Faron Pharmaceuticals to host investor R&D Day on bexmarilimab program

• Faron Pharmaceuticals will host an R&D Day webcast on Oct. 8, 2026.
• Event will review progress in the bexmarilimab clinical program across hematological cancers, including high-risk MDS, plus selected solid tumors.
• Senior management will present alongside external clinical experts; session includes a panel Q&A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.